Navigation Links
Immune Response Linked to “Ghost” Parasites and Severely Congested Sinuss

Although it’s unclear why it’s so, scientists at Johns Hopkins have linked a gene that allows for the chemical breakdown of the tough//, protective casing that houses insects and worms to the severe congestion and polyp formation typical of chronic sinusitis.

A team of Hopkins sinus experts has found that the gene for the enzyme, acidic mammalian chitinase (AMCase), is up to 250 times more active in people with severe sinus inflammation that persists even after surgery when compared to patients in whom surgery is successful. Sinus surgery is usually the treatment of last resort for those who do not respond to drug therapy. But nearly one in 10 of those treated see symptoms return within weeks or months after surgery fails to keep open the nasal passages, scientists say.

The Hopkins report, published in the July issue of the American Journal of Rhinology, is believed to be the first to identify the enzyme’s presence in the nose and confirm its link to sinusitis.

“This finding does not mean that there are actually parasites in the nose causing sinusitis, but our study does lend support to the concept that really severe and persistent sinusitis may be a case of a misplaced immune response directed against parasites that are not really there,” says study lead author Andrew Lane, M.D., an associate professor at The Johns Hopkins University School of Medicine and director of its rhinology and sinus surgery center.

Previous research by other scientists had looked at the enzyme’s tie-ins to asthma, which, like nasal polyps, is an inflammatory response of the body’s immune system. The theory, Lane says, is that allergies and asthma result from genes that control the body’s defenses against parasites, but these genes are dormant in healthy people. However, when turned on by so-called ghost parasites, the potent inflammatory response is medically very difficult to control.

Researchers say that although chitin, a rigid chemical compound common to fungi, insects and roundworms, is not naturally found in the human body, the presence of its corresponding enzyme and its role in the buildup of mucus and fluids, and polyp formation makes the enzyme a legitimate target for drug therapies to block its production and action.

“If we can selectively shut down the antiparasite immune response, we could potentially have new treatments for these airway diseases of the lung and nose,” says Lane.

New therapies are needed, he says, as an alternative to long-term steroids, which block the inflammatory chemical pathway but also have debilitating side effects, including loss of bone density, cataracts in the eye and weight gain.

An estimated 32 million Americans suffer from persistent inflammation of the tissue that lines the nasal and sinus cavities, according to the United States Centers for Disease Control and Prevention.

Thirty-three men and women participated in the two-year study at Hopkins, designed to find out if any of the genetic traits already known to be common in asthmatics were as active in patients with sinusitis. Twenty-two were scheduled to have surgery for sinusitis, while the remaining 11 served as study controls, having surgery for some other ailment than sinusitis.

All those who underwent sinus surgery did so after standard therapy using antibiotics, decongestants and steroids had failed to stop their symptoms and keep their sinus inflammation from coming back. They also had nasal polyps, or tissue outgrowths resulting from the inflammation, which, Lane says, are particularly hard to treat.

In the surgery, a thin, tube-like endoscope is inserted into the nose, with a camera attached to provide a close-up view of the nasal and sinus passages. Slender surgical instruments placed alongside the endoscope allow surgeons to cut away inflamed tissue and polyps, clearing a path for the sinuses to drain normally. Lane says that if left untreated, polyps can lead to severe blockage and recurring infections.

All patients were monitored for a minimum of nine months to see if polyps and their resulting symptoms returned. Ten in the surgery group had their polyps return within six months, while 12 remained symptom free.

The Hopkins team took samples during surgery of the mucous membrane lining the nose, and using real-time polymerase chain reaction tests, analyzed the samples for any genetic differences between the groups.

When researchers initially compared all the nasal tissue samples, they found that half had the gene for AMCase turned on, or expressed, to make the chitinase protein. During follow up, they found that the 10 patients who had their polyps return had exceedingly higher levels of AMCase expression than the other sinusitis patients and controls. Gene expression of another inflammatory protein, called interleukin-13, already known to be high in asthmatics, was also found to be elevated in those with polyps, but the levels of interleukin-13 did not have the same predictive value as the elevated expression of AMCase, researchers say.

Lane adds that future research will have to determine if high genetic expression of AMCase is an underlying cause of inflammation or if AMCase is simply one of many chemicals produced by cells in the nose in response to chronic inflammation.

The next phase of their research, he says, is to look for what triggers the anti-parasite response. However, Lane cautions that this reaction against parasites may come at the expense of the nose’s ability to ward off other invaders, such as bacteria, viruses or fungi.

“The epithelial cells lining the nasal and sinus cavities play an important role as first responders of the immune system,” he says. “But when they are distracted fighting non-existent parasites, they cannot deal well with the very real microbes continuously coming into the nose.”

This, Lane notes, may promote growth of bacteria and fungi in the nose, which is a common finding in those with chronic sinusitis with polyps.



Source-Nwswise
SRM
'"/>




Related medicine news :

1. Immune cells halt round in space
2. Immune function could benefit from exercise
3. Reviving the Immune System
4. Wrestling found To Be Good for the Immune System
5. Immune Boost With LHRH To Help Cancer And Transplant Patients
6. Researchers Find Out The Cause Of Immune Attacks Behind Hearing Loss
7. Block Immune System Chemical For Treating Asthma
8. Immune Response Of Human Beings Can Be Re-energized
9. Weizmann Institute of Science says Immune Cells Could Help Maintain Brain Function
10. Antidepressant drugs interacts with Immune cells
11. Specific Immune Mechanism against DNA viruses
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:1/23/2017)... ... January 23, 2017 , ... Old School Labs™, makers of the wildly ... Physique bodybuilder Breon Ansley to its growing team of brand ambassadors. The Olympia top ... and in less than a year was able to turn professional, participating in the ...
(Date:1/23/2017)... , ... January 23, 2017 ... ... (SNP) has launched online education programs and resources at seafoodnutrition.org/programs and seafoodnutrition.org/resources ... benefits of a seafood-rich diet. These resources have been developed for use ...
(Date:1/22/2017)... ... , ... Zifam Pinnacle, an Australian company dedicated to providing a unique range ... at the January ECRM Trade Show in Hilton Head, SC. , Zifam Pinnacle develops ... all of its creations to help create a more traditional and natural approach to ...
(Date:1/21/2017)... California (PRWEB) , ... January 21, 2017 , ... "ProDOF is the perfect set of ... subject to another subject in a scene," said Christina Austin - CEO of Pixel Film ... given scene. Easily create the illusion of a DSLR racking focus from one area ...
(Date:1/21/2017)... (PRWEB) , ... January 21, 2017 , ... ... of its new medical office in Petaluma, located at 167 Lynch Creek Way. ... access to SRO sports medicine and rehabilitation services and on-site x-ray ...
Breaking Medicine News(10 mins):
(Date:1/23/2017)... SAN DIEGO and PALMA, ... Laboratoris Sanifit S.L., a clinical-stage biopharmaceutical ... announced that the first patient has been enrolled ... of lead candidate, SNF472, for the treatment of ... haemodialysis (HD). Most ESRD patients, in ...
(Date:1/23/2017)... Jan. 23, 2017 Just two weeks remain until legal experts ... gather in Central London to discuss the flow ... in the market, Parallel Trade 2017 . In the ... of attendees which is available to read in the event download ... Some of ...
(Date:1/21/2017)... ResMed (NYSE: RMD ), BMC ( ... Florida ) today announced they have agreed on a global ... be permitted to sell their existing products in exchange for royalty ... to 3B to close the Florida litigation ... of liability or wrongdoing by any party. The ...
Breaking Medicine Technology: